

2. (Amended) The method of claim 1, wherein the target cell is a cancer cell.

3. (Amended) A method of inducing a cytotoxic response against a virus-infected cell, in a mammal, the method comprising:

B2 administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a virus-infected cell and a cytokine, and (ii) an angiogenesis inhibitor,

wherein the combination induces a cytotoxic immune response against the virus-infected cell that is greater than a response induced by the immunoconjugate alone.

Sub C3) B3 8. (Amended) The method of claim 1, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) the cytokine.

Sub C5) B4 12. (Amended) A method of inducing a cytotoxic immune response against a cancer cell in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a cancer cell and a cytokine, and (ii) an angiogenesis inhibitor selected from the group consisting of endostatin and angiostatin,

wherein the combination induces a cytotoxic immune response against the cancer cell that is greater than a response induced by the immunoconjugate alone.

Sub C6) B5 17. (Amended) The method of claim 12, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) the cytokine.

Sub C9) B6 20. (Amended) A composition for inducing an immune response against a target cell in a mammal, the composition comprising in combination:

(i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell and a cytokine, and (ii) an angiogenesis inhibitor,

wherein the combination induces a cytotoxic immune response against the target cell that is greater than a response induced by the immunoconjugate alone.

Sub C10/ B8 23. (Amended) The composition of claim 20, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) the cytokine.

B8 27. (Amended) The composition of claim 20, wherein the target cell is a cancer cell.

Sub C11/ B8 31. (Amended) A method for reducing the size of a tumor in a mammal, the method comprising:

administering to a mammal (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a tumor and a cytokine, and (ii) an angiogenesis inhibitor

wherein the combination induces a reduction in size of the tumor that is greater than a reduction in size induced by the immunoconjugate alone.

Sub C13/ B8 36. (Amended) The method of claim 31, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell, an immunoglobulin CH2 domain, and (ii) the cytokine.

REMARKS

Claims 1-39 were considered. Claims 1-2 and 4-39 were rejected. Claim 3 was objected to. Applicant amends claims 1, 2, 3, 8, 12, 17, 20, 23, 27, 31, and 36. Accordingly, after entry of this Amendment, claims 1-39 will be pending for examination. Applicant submits that the amendments introduce no new matter and that claims 1-39 are in condition for allowance.

Amendments to the Claims

Independent claim 1 is amended to recite "a target antigen expressed on a target cell." Dependent claims 2 and 8 are amended to conform their language to that of independent claim 1. Claim 3 is rewritten as an independent claim. Independent claim 12 is amended to recite "a target antigen expressed on a cancer cell." Dependent claim 17 is amended to conform to the language of independent claim 12. Independent claims 20 and 31 are amended to recite "a target antigen expressed on a target cell." Accordingly, dependent claims 23, 27, and 36 are amended to conform to the language of the independent claims. Support for these amendments is found in the application as filed, for example, at least on page 9, lines 14-22; page 15, lines 3-